By Jeffrey T. Donner, Esq.

August 3, 2026

The official history of the Tour de France contains a seven-year void.

Lance Armstrong finished first in the Tour every year from 1999 through 2005. After the United States Anti-Doping Agency established a systematic doping program involving EPO, blood transfusions, testosterone, corticosteroids, concealment, and coordinated team practices, Armstrong received a lifetime ban and lost all competitive results dating from August 1, 1998. No runner-up was declared the winner. The record books simply identify no Tour champion for seven consecutive years.

That punishment served a legitimate purpose. It demonstrated that an athlete cannot secure permanent immunity merely by defeating the testing methods available during his career. Doping can be proved through testimony, documents, admissions, stored samples, and other evidence. A sophisticated concealment system should not function as a statute of repose.

But the resulting historical record is also artificial. The races occurred. Armstrong finished first. Millions watched him do it. The titles were not reassigned because the riders immediately behind him were themselves deeply compromised. The official blank years therefore express condemnation, but they do not accurately describe what happened on the road.

A more candid record would say:

Lance Armstrong finished first in the 1999–2005 Tours de France; those results were later disqualified for systematic anti-doping violations; no replacement winners were designated.

That formulation would not excuse Armstrong or restore his legal titles. It would simply distinguish historical fact from subsequent disciplinary status.

The Armstrong case also raises a broader question: Is the current anti-doping regime the only coherent way to regulate elite sport?

This is not an argument that Armstrong raced clean. He did not. It is not a defense of his denials, his attacks on accusers, or his use of litigation and public pressure against people who challenged him. Nor is it a proposal to permit athletes to ingest unlimited quantities of hormones, stimulants, blood products, or experimental drugs.

It is an argument that the boundary between socially accepted medicine and prohibited athletic enhancement is less obvious and less consistent than it is usually presented.

Phil Liggett’s “racehorse” point

In a recent NBC interview, longtime Tour de France commentator Phil Liggett revisited his relationship with Armstrong and his own role in promoting the Armstrong story. Liggett admits that he wanted to believe the cancer-survivor narrative. Armstrong survived advanced testicular cancer, returned to elite cycling, won the Tour repeatedly, and used his fame to raise enormous sums for cancer advocacy.

Liggett also makes an important point: Armstrong was already an extraordinary athlete.

Pharmacology cannot turn an ordinary cyclist into a Tour champion. A rider must begin with unusual genetics, aerobic capacity, discipline, pain tolerance, tactical intelligence, and psychological resilience. As Liggett puts it, the athlete must first be a racehorse.

Armstrong became road world champion at age 21, before cancer and years before his Tour victories. The prohibited program enhanced an exceptional athlete; it did not manufacture one from nothing.

That does not make the drugs inconsequential. In a three-week race, a modest improvement in oxygen delivery, recovery, sustainable power, or resistance to fatigue can decide the outcome. But it is equally misleading to suggest that Armstrong won merely because he possessed the best pharmacy.

The unanswered question is whether he would have beaten the same rivals in a genuinely drug-free sport. Nobody can know, because no clean version of the 1999–2005 peloton existed for comparison.

“Everyone was doing it” is not a complete legal defense. It is, however, relevant to comparative blame and historical fairness. If doping was pervasive among the principal contenders, Armstrong’s conduct remains wrongful, but the idea that his removal restored a clean and legitimate result becomes difficult to sustain.

Jacques Anquetil’s challenge

In the same interview, Liggett discusses Jacques Anquetil, the first five-time winner of the Tour de France and a former holder of the world hour record.

Anquetil was unusually candid about pharmacological assistance. He treated professional cyclists as workers performing an extraordinarily demanding occupation. If an office worker could take medication to control a headache and finish the day, he asked, why should a cyclist be expected to endure extreme pain, exhaustion, and physical depletion without medical help?

The analogy is imperfect. An office worker taking an analgesic does not ordinarily force every colleague to take the same drug to remain competitive. A cyclist using EPO or anabolic agents may create pressure on every rival to assume comparable risks.

Still, Anquetil identified a real inconsistency. Modern society does not oppose drugs merely because they alter human performance.

We use anesthesia to make surgery possible, chemotherapy and immunotherapy to fight cancer, antiretroviral drugs to suppress HIV, insulin to replace a deficient hormone, stimulants to improve attention, antidepressants to alter mood, and testosterone to treat certain endocrine deficiencies. Older adults commonly take multiple medications to preserve life, reduce pain, and maintain function.

The law itself recognizes that the same substance may be medically useful and potentially dangerous. Amphetamine products may be lawful when prescribed and unlawful when possessed or distributed outside the regulatory system. Testosterone may be legitimate treatment in one context and prohibited enhancement in another.

The central distinction is therefore not between “drugs” and “no drugs.” It depends on purpose, dosage, risk, supervision, authorization, and institutional rules.

Elite sport is already enhanced

The modern athlete is not “natural” in any ordinary sense.

Elite competitors use altitude training, simulated-altitude environments, advanced nutrition, caffeine, legal supplements, surgery, biomechanical analysis, recovery technology, sports psychology, glucose monitoring, aerodynamic equipment, power meters, wind tunnels, and teams of physicians and scientists.

Cycling itself is inseparable from performance-enhancing technology. Carbon frames, aerodynamic wheels, optimized tires, electronic shifting, skinsuits, helmets, and laboratory testing all allow riders to perform better than the same bodies could perform with older equipment.

That does not mean EPO is morally equivalent to a carbon wheel. Internal biological manipulation may create different health risks and may be harder to regulate. But it does mean that “enhancement is unnatural” is not a serious explanation of anti-doping policy.

The real question is which enhancements a sport chooses to permit and why.

Each sport defines a bounded form of excellence. Cycling permits bicycles but prohibits hidden motors. It permits altitude training but prohibits EPO. It permits caffeine but restricts stronger stimulants. Those boundaries may be rational, but they are constructed rules, not laws of nature.

The enforcement problem

The strongest argument against doping is that secret enhancement violates rules accepted by other competitors.

Armstrong’s conduct was wrong in that basic sense. He participated in a prohibited system, concealed it, denied it, and attacked people who threatened to expose it.

But imperfect enforcement creates another form of unfairness.

The clean athlete may be disadvantaged. The unsophisticated doper may be caught. The better-funded athlete may obtain superior medical advice, shorter detection windows, more precise dosing, cleaner products, or better concealment.

A negative test establishes only that a prohibited substance or method was not detected in that sample under the available procedures. It does not prove that no doping occurred.

Armstrong exploited that distinction. He repeatedly pointed to his testing history as though the absence of an official positive established innocence. It did not. His eventual case was proved through converging testimony, documents, admissions, stored-sample evidence, and other corroboration.

Testing has improved, but no anti-doping system can eliminate microdosing, new compounds, physiological variation, detection windows, and unequal access to sophisticated medical programs.

As a result, every extraordinary performance now carries suspicion. A clean athlete may be doubted because earlier champions deceived the public. A doped athlete may remain celebrated because the relevant method is never detected.

The system intended to preserve confidence can therefore perpetuate uncertainty.

Why unrestricted doping is not the answer

The alternative cannot simply be: let every athlete take anything.

Modern bodybuilding demonstrates why.

At the highest level of Men’s Open Bodybuilding, competitors display muscular size and conditioning far beyond ordinary human proportions. It is widely understood that pharmacology plays a major role in that environment, although it would be irresponsible to accuse any particular athlete of using a specific substance without evidence.

The structural point is obvious. When the contest rewards maximum size and extreme conditioning, and pharmacological tools are available, competitors face pressure to escalate. What begins as enhancement can become an arms race in dosage, combinations, experimental compounds, and willingness to accept long-term medical risk.

Bodybuilding has partly responded by creating alternative categories. Classic Physique imposes height-related weight limits. Men’s Physique rewards a different appearance. Separate natural-bodybuilding organizations and contests claim to impose drug-testing requirements.

Those categories are not interchangeable, and Classic Physique is not necessarily a drug-free division. But their existence reflects a basic truth: more enhancement does not always produce a more attractive or meaningful competition.

Few people want cycling or track to become a contest in which victory belongs primarily to the athlete willing to tolerate the most aggressive chemical regimen. The audience wants extraordinary speed, endurance, courage, skill, and strategy—not merely a pharmaceutical extremity contest.

Unrestricted doping would also create coercion. Once a substance creates a meaningful advantage, every rival may feel compelled to use it. A formal right to refuse becomes meaningless if refusal ends any realistic chance of competing.

The problem becomes more serious because elite development begins before adulthood. A permissive professional culture would inevitably influence teenagers, coaches, parents, and junior programs.

Medical supervision would help, but it would not eliminate risk. Team physicians may face conflicts of interest. Monitoring cannot make every intervention safe. Wealthy athletes would still obtain better products, physicians, and risk management than poorer competitors.

For those reasons, a total chemical free-for-all is not a defensible solution.

A separate regulated enhanced category

A more serious alternative would preserve conventional drug-tested sport while permitting a separate adult-only enhanced category.

That system would require strict limits:

• No minors.
• Independent physicians rather than team-controlled prescribing.
• A limited list of permitted substances.
• Dosage ceilings and physiological safety thresholds.
• Mandatory cardiac, endocrine, liver, kidney, blood-pressure, and psychiatric monitoring.
• Full regulatory disclosure.
• Prohibition of black-market and experimental compounds.
• Separate records and championships.
• Strong penalties for undisclosed substances or excess dosing.
• A protected right to refuse a proposed drug without retaliation.

This would not be “anything goes.” It would be a different regulated sport.

The conventional division would preserve the right of athletes to compete without being pressured into pharmacological enhancement. The enhanced division would test whether transparent, limited, medically monitored assistance can be regulated more honestly than clandestine doping.

Perhaps it would fail. Perhaps the medical risks and competitive pressures would prove impossible to control. Perhaps audiences would reject it. Those possibilities justify caution. They do not justify refusing to consider the question.

The cancer paradox

Armstrong’s life presents the issue in its most striking form.

Medicine first saved him. Surgery and chemotherapy treated advanced cancer. Pharmacology was celebrated because it preserved life.

Later, pharmacology helped invalidate the athletic achievements that made him famous.

There is no direct contradiction. Cancer treatment and athletic enhancement have different purposes, different risks, and different effects on other people. One patient’s chemotherapy does not compel another patient to accept the same treatment to remain competitive. Doping in elite sport can pressure every rival.

But the irony remains.

Society enthusiastically uses science to extend life, relieve pain, sharpen attention, restore function, and increase productivity. At the same time, it often speaks as though sport must emerge from an untouched natural body, even while permitting extensive surgery, technology, nutrition, and medical intervention.

The coherent defense of anti-doping is not that drugs are inherently evil. It is that certain forms of internal enhancement create unacceptable health risks, coercive pressure, and distortion of the agreed competition.

That defense is serious. It is not beyond criticism.

Armstrong’s good works and bad conduct

A fair assessment must also hold contradictory facts at once.

Armstrong doped systematically. He lied. He attacked accusers and used his public reputation aggressively.

He was also an extraordinary athlete.

His cancer advocacy raised enormous sums and helped many people. That public good does not disappear because the athletic platform supporting it was compromised.

Nor does the charitable work excuse the doping.

Moral judgment is not a single-column ledger in which one fact cancels another. Armstrong can be a gifted athlete, a systematic doper, a dishonest public figure, and a person whose cancer advocacy produced genuine good.

Liggett’s ambivalence is therefore understandable. He feels betrayed because Armstrong allowed him to invest his voice and reputation in a false story. Yet he continues to admire Armstrong’s athletic ability and recognizes the value of the cancer work.

Conclusion

Lance Armstrong violated the rules of professional cycling and deserved a serious sanction. The evidence against him extended far beyond one failed test. His conduct included an organized doping program, concealment, repeated denials, and attacks on accusers.

Yet he also competed in an era in which doping was pervasive, testing was imperfect, and many plausible replacement winners were themselves compromised. Leaving seven Tours without winners expresses institutional condemnation but produces a historically incomplete record.

Jacques Anquetil’s challenge remains relevant. Society permits pharmacology to preserve life, reduce pain, improve attention, restore function, and extend productive capacity. Why must elite sport maintain a special form of pharmacological prohibition?

The answer cannot simply be that drugs are bad. Modern sport already permits extensive technological, medical, nutritional, and surgical enhancement.

The better defense of anti-doping rests on competitive consent, health protection, prevention of coercion, protection of minors, and preservation of the kind of excellence the sport intends to measure.

Bodybuilding demonstrates why unrestricted enhancement can become an arms race in extremity. No sensible reform should invite cycling or track to reproduce that model.

But the failures of unrestricted enhancement do not prove that the current system is the only legitimate one. A separate, adult-only, medically regulated enhanced category deserves serious consideration.

Perhaps it would not work. But a civilized debate should be able to examine the possibility without collapsing into slogans.

Armstrong was an extraordinary athlete. He doped. Many of his rivals doped. He lied and treated accusers badly. His cancer advocacy produced genuine public benefit. His victories occurred and were later invalidated.

All of those facts can be true at the same time.

A mature discussion of drugs in sport should be capable of holding them.